[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643360":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":39,"centralContacts":40,"locations":46,"responsibleParty":75,"collaborators":39,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":39,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":85,"minAge":86,"maxAge":39,"enrollmentInfo":87,"targetDuration":39,"studyType":90,"phases":91,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":49,"whyStopped":39,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Atavistik Bio, Inc","INDUSTRY",[8,14,17,21],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: 60 mg QD","EXPERIMENTAL","Active drug, once daily",[13],"Drug: ATV-1601",{"label":15,"type":10,"description":11,"interventionNames":16},"Part 1: 100 mg QD",[13],{"label":18,"type":10,"description":19,"interventionNames":20},"Part 1: 60 BID","Active drug, twice daily",[13],{"label":22,"type":10,"description":23,"interventionNames":24},"Part 1: Placebo","Control Arm",[25],"Drug: Placebo",[27,34],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","ATV-1601","Administered orally, daily",[15,18,9],[33],"Active drug, capsule",{"type":28,"name":35,"description":30,"armGroupLabels":36,"otherNames":37},"Placebo",[22],[38],"Inactive, Placebo",null,[41],{"name":42,"role":43,"phone":44,"phoneExt":39,"email":45},"Study Director","CONTACT","857-285-5400","Studydirector@atavistikbio.com",[47,63],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Massachusetts General Hospital","RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-71.05977,42.35843,{"lat":59,"lon":58},[62],{"name":42,"role":43,"phone":39,"phoneExt":39,"email":39},{"facility":64,"status":49,"city":65,"state":66,"zip":67,"country":53,"countryCode":54,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Mayo Clinic","Rochester","Minnesota","55905",{"type":56,"coordinates":69},[70,71],-92.4699,44.02163,{"lat":71,"lon":70},[74],{"name":42,"role":43,"phone":39,"phoneExt":39,"email":39},{"type":76,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR","100643360","phase-1-harmony-hht-atv-1601-in-participants-with-hereditary-hemorrhagic-telangiectasia-hht-100643360",false,"NCT07601425","Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)","A Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study of ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)","Inclusion Criteria:\n\n* Ability to provide informed consent prior to any study-specific procedures\n* Confirmed diagnosis of hereditary hemorrhagic telangiectasia (HHT) based on Curaçao criteria\n* Moderate to severe HHT with an ESS ≥ 4\n* Anemia at Screening and\u002For requirement for at least 1 red-cell unit (RUE) in the previous 6 months\n* Adequate hematologic, renal, and hepatic function per protocol-defined laboratory criteria\n* Use highly effective contraception during the study and for a protocol-defined period after last dose\n\nExclusion Criteria:\n\n* Clinically significant abnormalities of glucose metabolism including diagnosed Type 1 or uncontrolled Type 2 diabetes\n* Chronic cardiac disease, or cardiac rhythm abnormalities\n* History of significant cardiovascular, hepatic, renal, or hematologic disease not related to HHT that may confound study results\n* Use of prohibited concomitant medications within a protocol-defined washout period prior to first dose (including strong CYP modulators and certain herbal supplements)\n* Recent (within 6 weeks) major surgery or local ablative procedures, or procedures on nasal telangiectasias\n* Prior AKT inhibitor\n* Pregnant or breastfeeding women\n\nAdditional Criteria for Open-Label Extension:\n\n* Participants must complete the double-blind treatment period (Part 1)",true,"ALL","18 Years",{"count":88,"type":89},100,"ESTIMATED","INTERVENTIONAL",[92,93],"PHASE1","PHASE2","This is a 2-part study evaluating ATV-1601 in participants with moderate to severe HHT. Part 1 is a randomized, double-blind, placebo-controlled study evaluating 3 dosing regimens of ATV-1601. Patients completing Part 1 may participate in the Part 2 open-label extension to receive ATV-1601.",[96,97],"Hereditary Hemorrhagic Telangiectasia (HHT)","Osler Weber Rendu Disease",[99,29,100,101,102,103,104,105,106,107,108,109,110,111,112],"Arteriovenous malformations","HarmonyHHT","Harmony-HHT","HarmonyHHTStudy","Vascular Diseases","Bleeding disorders","Hematologic disorders","Disorders","Telangiectasias","Hereditary hemorrhagic","Hemorrhagic disorders","Cardiovascular diseases","Vascular malformations","HHT","2026-08-14",{"date":115,"type":116},"2026-08-17","ACTUAL",{"date":118,"type":116},"2026-07-27",{"date":120,"type":89},"2030-03",{"name":5,"class":6},2]